Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11011269 | 0.89 | GPBAR1 (0.72) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL9760003 | 0.89 | GPBAR1 (0.72) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL933404 | 0.88 | CYP2D6 (0.67) | POLA1CDC25ALMNAMEN1KMT2A | |
| SCHEMBL16860684 | 0.88 | CYP2D6 (0.67) | POLA1CDC25ALMNAMEN1KMT2A | |
| SCHEMBL4624060 | 0.86 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL3125136 | 0.86 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL21257887 | 0.86 | GRIN2A (0.57) | GPBAR1CDC25AHSD17B10TDP1AKR1B10 | |
| SCHEMBL1490581 | 0.86 | GPBAR1 (0.55) | GPBAR1POLA1CDC25AHSD17B10TDP1 | |
| SCHEMBL6879512 | 0.86 | GPBAR1 (0.55) | GPBAR1POLA1CDC25AHSD17B10TDP1 | |
| SCHEMBL11057706 | 0.85 | GPBAR1 (0.75) | GPBAR1POLA1CDC25AHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3593143-B1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2024-11-27 | — | — | EP | claimed |
| US-11650212-B2 | Screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios | ACADEMISCH MEDISCH CENTRUM (NL) | 2023-05-16 | — | — | US | claimed |
| US-20210033626-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2021-02-04 | — | — | US | claimed |
| WO-2018162362-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | ACADEMISCH MEDISCH CENTRUM (NL) | 2018-09-13 | — | — | WO | claimed |
| US-20100113286-A1 | METHODS FOR DETECTION OF PREECLAMPSIA | LAJOIE GILLES ANDRE | 2010-05-06 | — | — | US | claimed |
| EP-2147309-A1 | METHODS FOR THE DETECTION OF PREECLAMPSIA | The University Of Western Ontario (CA) | 2010-01-27 | — | — | EP | claimed |
| WO-2008134881-A1 | METHODS FOR THE DETECTION OF PREECLAMPSIA | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2008-11-13 | — | — | WO | claimed |
| EP-3593143-B1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2024-11-27 | — | — | EP | disclosed |
| CN-108430514-B | Compositions and methods for treating peroxisome disorders and leukodystrophies | 约翰霍普金斯大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-3368088-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11650212-B2 | Screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios | ACADEMISCH MEDISCH CENTRUM (NL) | 2023-05-16 | — | — | US | disclosed |
| US-20220071923-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES | KENNEDY KRIEGER INSTITUTE, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20210033626-A1 | A SCREENING METHOD FOR CEREBROTENDINOUS XANTHOMATOSIS USING BILE ALCOHOL GLUCURONIDES AND METABOLITE RATIOS | Stichting Amsterdam UMC (NL) | 2021-02-04 | — | — | US | disclosed |
| WO-2016019176-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND CONFIRMING PREECLAMPSIA | COOPER MATTHEW (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20120004854-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-01-05 | — | — | US | disclosed |
| EP-2279417-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | Georgia Tech Research Corporation (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100113286-A1 | METHODS FOR DETECTION OF PREECLAMPSIA | LAJOIE GILLES ANDRE | 2010-05-06 | — | — | US | disclosed |
| EP-2147309-A1 | METHODS FOR THE DETECTION OF PREECLAMPSIA | The University Of Western Ontario (CA) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009151967-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2008134881-A1 | METHODS FOR THE DETECTION OF PREECLAMPSIA | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071923-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PEROXISOMAL DISORDERS AND LEUKODYSTROPHIES | CLN6, PEX3, GBA1 | GPBAR1 1628/4885POLA1 1026/4885CDC25A 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.